Skip to search formSkip to main contentSkip to account menu

ASP2151

Known as: ASP 2151 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background and ObjectivesThe helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved… 
2017
2017
IntroductionAmenamevir is a nonnucleoside antiherpes virus compound available for treating herpes zoster infections. Four studies… 
2017
2017
IntroductionAmenamevir (ASP2151) is a nonnucleoside human herpesvirus helicase-primase inhibitor that was approved in Japan for… 
Review
2013
Review
2013
Highly Cited
2012
Highly Cited
2012
BACKGROUND Current therapies for genital herpes have only partial efficacy. Helicase-primase inhibitors are novel, potent… 
2012
2012
ABSTRACT ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster… 
2012
2012
ABSTRACT ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella… 
2011
2011
ASP2151 is a herpesvirus helicase-primase inhibitor with antiviral activity against varicella zoster virus and herpes simplex… 
Review
2011
Review
2011
Introduction: Varicella-zoster virus (VZV) is the etiological agent of two distinct diseases, varicella (chickenpox) and shingles… 
Highly Cited
2010
Highly Cited
2010
OBJECTIVES To evaluate and describe the anti-herpesvirus effect of ASP2151, amenamevir, a novel non-nucleoside oxadiazolylphenyl…